KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentBeginning Cash BalanceBeginning Cash BalanceCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Change in Accured Expenses (2017 - 2026)

Amneal Pharmaceuticals has reported Change in Accured Expenses over the past 9 years, most recently at $18.6 million for Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 71.96% year-over-year to $18.6 million; the TTM value through Dec 2025 reached $21.3 million, down 90.93%, while the annual FY2025 figure was $21.3 million, 90.93% down from the prior year.
  • Change in Accured Expenses for Q4 2025 was $18.6 million at Amneal Pharmaceuticals, down from $69.7 million in the prior quarter.
  • Over five years, Change in Accured Expenses peaked at $322.7 million in Q2 2022 and troughed at -$150.5 million in Q1 2023.
  • A 5-year average of $11.4 million and a median of $17.3 million in 2021 define the central range for Change in Accured Expenses.
  • On a YoY basis, Change in Accured Expenses climbed as much as 1905.87% in 2022 and fell as far as 828.86% in 2022.
  • Year by year, Change in Accured Expenses stood at -$11.1 million in 2021, then plummeted by 402.74% to -$55.9 million in 2022, then surged by 64.63% to -$19.8 million in 2023, then surged by 435.29% to $66.3 million in 2024, then crashed by 71.96% to $18.6 million in 2025.
  • Business Quant data shows Change in Accured Expenses for AMRX at $18.6 million in Q4 2025, $69.7 million in Q3 2025, and $45.6 million in Q2 2025.